🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced/Metastatic Solid Tumors

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048Phase 11 site📍 Hangzhou Weijia Fang, MD · Tests: Intraperitoneal infusion of FAST CEA-targeted CAR-T A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. NCT04116541Phase 213 sites📍 Angers📍 Bordeaux📍 Caen Centre Leon Berard · Tests: HDM201, Ribociclib, Cabozantinib, Alectinib, Regorafenib AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors NCT07469982Phase 11 site📍 Shanghai Shouyao Holdings (Beijing) Co. LTD · Tests: SY-9453 Imaging of Solid Tumors Using 18F-TRX NCT06942104Phase 11 site📍 San Francisco Rahul Aggarwal · Tests: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 NCT06410092Phase 13 sites📍 Beijing📍 Chongqing📍 Chengdu Sound Biopharmaceuticals Ltd. · Tests: FTL001 Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors NCT05631964Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1 Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06960395Phase 14 sites📍 Scottsdale📍 Houston📍 Wollongong Vir Biotechnology, Inc. · Tests: VIR-5525, Pembrolizumab Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors NCT07415863Phase 1, Phase 21 site📍 Beijing CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6043 PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors NCT07510828Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-PT-CAR-NK-S, EB-PT-CAR-NK-D, Lymphodepleting chemotherapy, Cytokine support A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270Phase 12 sites📍 Zhengzhou📍 Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Tests: SYN818 BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study NCT07269080Phase 11 site📍 Chicago University of Illinois Chicago · Tests: Ablative radiation treatment RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569n/a1 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Trastuzumab deruxtecan (DS-8201a) A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors NCT07056556Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M09D1 Study of ACR-2316 in Specific Advanced Solid Tumors NCT06667141Phase 1, Phase 215 sites📍 Phoenix📍 Beverly Hills📍 Newport Beach Acrivon Therapeutics · Tests: ACR-2316 A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) NCT06521554Phase 121 sites📍 Irvine📍 Sacramento📍 Stanford Nuvalent Inc. · Tests: NVL-330 A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06493864Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B16D1 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607Phase 298 sites📍 Los Angeles📍 Baltimore📍 New York AstraZeneca · Tests: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy